| Literature DB >> 30840885 |
Yukinori Terada1, Norihide Jo2, Yoshiki Arakawa3, Megumi Sakakura4, Yosuke Yamada2, Tomoyo Ukai4, Mio Kabata2, Kanae Mitsunaga2, Yohei Mineharu3, Sho Ohta5, Masato Nakagawa2, Susumu Miyamoto3, Takuya Yamamoto6, Yasuhiro Yamada7.
Abstract
Atypical teratoid/rhabdoid tumor (AT/RT), which harbors SMARCB1 mutation and exhibits a characteristic histology of rhabdoid cells, has a poor prognosis because of the lack of effective treatments. Here, we establish human SMARCB1-deficient pluripotent stem cells (hPSCs). SMARCB1-deficient hPSC-derived neural progenitor-like cells (NPLCs) efficiently give rise to brain tumors when transplanted into the mouse brain. Notably, activation of an embryonic stem cell (ESC)-like signature confers a rhabdoid histology in SMARCB1-deficient NPLC-derived tumors and causes a poor prognosis. Consistently, we find the activation of the ESC-like gene expression signature and an ESC-like DNA methylation landscape in clinical specimens of AT/RT. Finally, we identify candidate genes that maintain the activation of the ESC-like signature and the growth of AT/RT cells. Collectively, SMARCB1-deficient hPSCs offer the human models for AT/RT, which uncover the role of the activated ESC-like signature in the poor prognosis and unique histology of AT/RT.Entities:
Keywords: ESC-like signature; SMARCB1; atypical teratoid/rhabdoid tumor; dedifferentiation; embryonic stem cell; induced pluripotent stem cell; pediatric tumor; pluripotency
Mesh:
Year: 2019 PMID: 30840885 DOI: 10.1016/j.celrep.2019.02.009
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423